thalidomide has been researched along with Hormone-Dependent Neoplasms in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Once, prostate cancer becomes hormone-refractory, there are only a few effective therapies such as docetaxel-based chemotherapies." | 2.44 | [Molecular-targeted therapy for prostate cancer]. ( Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nabhan, C | 1 |
| Petrylak, DP | 1 |
| Ng, SS | 1 |
| Gütschow, M | 1 |
| Weiss, M | 1 |
| Hauschildt, S | 1 |
| Teubert, U | 1 |
| Hecker, TK | 1 |
| Luzzio, FA | 1 |
| Kruger, EA | 1 |
| Eger, K | 1 |
| Figg, WD | 1 |
| Mathew, P | 1 |
| Logothetis, CJ | 1 |
| Dieringer, PY | 1 |
| Chen, I | 1 |
| Pagliaro, LC | 1 |
| Bekele, BN | 1 |
| Zhou, X | 1 |
| Daliani, DD | 1 |
| Nonomura, N | 1 |
| Nakayama, M | 1 |
| Takayama, H | 1 |
| Nishimura, K | 1 |
| Okuyama, A | 1 |
2 reviews available for thalidomide and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
The role of IMiDs alone or in combination in prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lenalidom | 2012 |
[Molecular-targeted therapy for prostate cancer].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Neoplasms, Hormone-De | 2008 |
1 trial available for thalidomide and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Rin | 2006 |
1 other study available for thalidomide and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Topics: Adenocarcinoma; Androgens; Angiogenesis Inhibitors; Animals; Aorta; Cell Division; Drug Screening As | 2003 |